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on the Vi antigen has been developed also against S. ryphi. Conjugate
vaccines are being tested against Salmonella and Shigella.
531 - Osteomyelitis
Mt~ Diagnosis and management of the infected joint
prosthesis
D. Osmon
Mayo Clinic, Rochester, Minnesota, United States
The risk ofprosthetic joint infection (I'JI) in the more than 430.000 total hip
and total knee arthroplasties performed in the United States each year is low
(1-4%). The incidence rate ofPJI is highest in the first two years following
prosthesis implantation. but has occurred as late as 20 years following
implantation. In the majority of cases. pJI is due to Sraphylococcus aureus,
coagulase negative staphylococci and B-hemolytic streptococci. Infections
due to other organisms occur much less frequently. Most infections arc
thought to occur as a consequence of intraoperative contamination of the
prosthesis. Hematogenous seeding uf the prosthesis is much less commun.
This talk will focus on the epidemiology. diagnosis. treatment and
prevention of pJI. Topics that will be discussed include new classification
schemes for I'JI, information regarding risk factors for I'JI. as well as selected
cuntroversies in the medical and surgical management of I'JI. These COI1-
truversies include the role of debridement and retention of the prosthesis.
given recent data regarding the treatment of staphylococcal I'JI without
prosthesis removal using antimicrobial combinations that include rifampin.
Lastly. strategies to prevent I'JI in the preoperative. intraoperative and
postoperative period will be reviewed. including a summary of new
consensus guidelines for the use of antibiotic prophylaxis to prevent PJI
due to ural flora following dental procedures.
IWeS40 I The use of quinolones and rifampin for the
treatment of infected orthopedic devices
W. Zimmerli. P. E. Ochsner
Medical University Clinic ami Orrhopedic Clinic, KatltotlSspital, Liestal,
Switzerland
Infections. mostly caused by Sraphylococcus aurel/s or coagulase-negative
staphylococci. arc feared complication in orthopedic surgery. Betalactams
are not a good choice for long-term oral treatment of device-related
infections, bCC'3USC of their lack of activity on sJow-groVY'ing bacteria, and
their unfavorable bioavailability. Therefore. the treatment with quinolone/
rifampin has been studied in patients with infected orthopedic devices. In
observational studies. the success-rate was 62% (13/21) (AAC 37: 1214.
1993). and 82% (9/11) (CID 14: 1251. 1992) with retention ofthe device. In a
randomized. placebo-controlled study comparing ciprofloxacin/rifampin vs
ciprofloxacin/placebo. the superiority of the rifampin-regimen has been
documented with cure-rates of 100% (12/12) vs 58% (7/12) (JAMA 279:
1537. 1998). Such high cure-rates can only be obtained. if patients are
carefully selected. Prerequisites for long-term (3-6 months) treatment with
retention of the device are as follows: (I) early manifestation « 3 months)
or hematogeneous infection with a short history « 1 month). (2) stable
implant. (3) rifampin- and quinolone-susceptible staphylococci. (4) good
condition of bone stock and soft tissue (no sinus tract). (5) debridement
surgery. In patients with sinus tracts. quinolone/rifampin treatment should
not be given. because of the risk of exogenous superinfection with quino-
lone/rifampin resistant microorganisms. Before the explantation of the
device. such patients should be treated with either flucloxacillin or a
glycopeptide, according to the susceptibility of the staphylococci. The
quinolone/rifampin regimen should be started only after reimplantation in
a 2-stage exchange. Long-term therapy with quinolone plus rifampin is
expensive and may cause adverse events (nausea. anorexia). Therefore. only
microbiologically documented cases should be treated with this regimen. In
conclusion. the quinolone/rifampin-regimen is higWy efficacious. ifpatients
are carefully selected.
IWeS411 The use of antibiotic-containing bead chains in the
treatment of chronic bone infections
K.Klemm
B.G. Unfallklinik FrankfUrt/Main, Cffmany
Objectives: By application of Gentamicin PMMA bead chains into osteo-
myelitic cavities a local antibiotic therapy in concentrations far above the
MIC of most common pathogens can be execuded.
Methods: The bone cement PMMA serves as carrier material for the
protracted release of the antibiotic. In in vitro studies of WaWig et al. up
to 600 JLg/ml were measured by elution in the buffer solution on the 1st day
and on the 80th day there were still 10 JLg/ml gentamicin per bead in the
eluate. Under clinical conditions 80 to 200 JLg/ml ofGentamicin were found
in the wound secretion depending on the number ofimplanted beads. With
such high concentrations at the infection site the MIC breakpoint of
Gentamicin 4 JLg/ml were exceeded locally by a factor of more than 10
whereas only low concentrations were found in the serum and urine.
Nephrotoxic and ototoxic side effects arc not to be feared.
Surgical procedure: After debridement of all infected and devitalized
tissue the infected cavity is filled completely with the Gentamicin PMMA
chains. For high local concentrations primary wound closure is dispensable.
The chains are removed by extraction within 7 days or when a second
operation as bone grafting is indicated
Results: In 405 cases of temporary filling ofosteomyelitis cavities presented
at the 13th. Int. Congress of Chemotherapy 1983 in Vienna the success rate
was 96%.
conclusion: Gentamicin PMMA chains are effective and save in the opera-
tive treatment of chronic osteomyelitis of all forms.
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IMoG2-11 Genetic markers: can molecular typing reveal an
epidemiological association?
M. C. J. Maiden
WeI/come Trl/st Centre for the Epidemiology of lrifectiol/s Disease. Department
of Zoology, University ofOxford, South Parks Road Oxford, United Kingdom
Bacterial epidemiology requires precise isolate characterisation. The tech-
niques used to achieve this should combine appropriate levels ofdiscrimina-
tion with cost effectiveness and reproducibility. Increasingly. serological
typing schemes are being replaced with molecu1ar techniques, which often
employ fingerprinting approaches. Unfortunately. many novel techniques
are of limited value because they fail to take into account the population
structure of the bacterial species under investigation. This talk will provide
an overview of bacterial population biology and describe how the insights
obtained from this subject can be exploited in the development ofeffective
isolate characterisation techniques and in the investigation of bacterial
epidemiology.
IMoG2-21 Evaluation of endemic nosocomial transmission
and sources of infection with the help of molecular typing
D. S. Blanc
Centre Hospitalier Universitaire Va'4dois, 1011 Lausanne, Switzerland
While molecular typing methods are widely used to help the hospital
epidemiologist in the investigation of nosocomial outbreaks, their use for
the understanding of endemic nosocomial infections has been limited. The
identification of the source or reservoir is only possible with comprehensive
screening of the environment and the endogenous flora ofpatients and staff.
and therefore requires significant resources. However. cross-eontarnination
or the existence of a common exogenous source might be investigated
typing clinical isolates during non epidemic periods. Cross-eontamination is
suspected when isolates from different patients belong to the same type and
when an epidemiological relation can be established. Studies performed with
the three main nosocomial pathogenes. StaphylococClls al/rel/S, Escherichia coli
and Pseudomonas aeruginosa, have revealed complex situations which may
vary from one setting to another. While some data suggest that pre-existing
colonization at admission is the major source ofmicroorganisms responsible
for nosocomial infections. other shows that exogenous sources or cross-
contamination may account for an important part of these infections.
According to these studies. the proportion of isolates presumably acquired
through cross-eontamination or exogenous source may vary from 10 to
60% for P. arfllgillosa and from 0 to 21 % for E. coli. The situation ofS. aureus
is complex because of the existence ofclones which may be higWy prevalent
in the population. with no apparent epidemiological link. Some data
suggest, that the proportion of cross-eontamination is lower for methicil1in
susceptible S. aI/tellS than for MRSA. This property for dissemination has
alsu been described ti" other multiresistant nosocomial pathugen•.
